-
Stardco's performance grew steadily and a number of innovative products were released
Time of Update: 2021-03-08
150 years of experience with 64,000 units delivered for installation. Behind the familiar data is a brand new brand, Syntegon. In January 2020, Syntegon became the new name of the process and packagi
-
Paige Bio completes financing to advance the development of innovative drug pipelines for chronic diseases
Time of Update: 2021-03-08
Paige Bio is the leading domestic biotechnology company focused on the development of new drugs for chronic diseases, and has a number of clinical stage products, we are very optimistic about the company's layout and advantages in the field of the disease.
-
Tiansli Bio will be on the market
Time of Update: 2021-03-08
Tiansli announced that Chongqing Pharmaceuticals will further focus on the pharmaceutical industry and improve the quality of operations and the efficiency of capital utilization through the sale of commercial business assets by acquiring a 99.948 percent stake in Tiansli's subsidiary Tiansli Marketing for 1,489 million yuan.
-
Zhongsheng Pharmaceuticals intends to contribute $515 million to Cosing Zhongwei
Time of Update: 2021-03-08
On December 7, China Biopharmaceuticals announced that hong Kong Jun-Kel Co., Ltd., a wholly-owned subsidiary, had entered into an agreement to invest $515 million in beijing-based Kexing Zhongwei Biotechnology Co., Ltd. for further development, capacity expansion and production of the new crown inactivated vaccine Kellefo, as well as other development and operation activities of Kexing Zhongwei.
-
Meikang Bio plans to raise an additional 600 million yuan for in-body diagnostic product development
Time of Update: 2021-03-08
According to World Preview 2018, Outlook to 2024 released by Evaluate MedTech, global medical device market sales in 2017 were $405.00 billion, up 4.60% YoY; According to the China Medical Device Blue Book (2019 edition) published by the Institute of Medical Research, the market size of China's in-body diagnostic industry in 2018 was approximately 60.400 billion yuan, up 18.43% YoY from 2017.
-
Sichuan was the first to announce 25 varieties of payment standards brought about five major impacts
Time of Update: 2021-03-08
Previously, the State Health Insurance Administration and other nine departments issued "on the national organization of drug centralized procurement and use of the pilot expansion of regional scope of implementation opinion" clearly pointed out that the exploration of centralized procurement of pharmaceutical medical insurance payment standards and procurement price synergy.
-
Hua dao Bio completed nearly 200 million yuan C round of financing
Time of Update: 2021-03-08
Founded in September 2017, Huadao Bio focuses on the development of autologic CAR-T cell therapy products for hematomas and solid tumors, as well as the independent innovation of the entire industry chain of the cell immunotherapy industry.
-
CRO's leading company, Pharmaceuticals, announced the acquisition of a 60% stake in Mingjie Pharmaceuticals
Time of Update: 2021-03-08
In February this year, the company through its wholly-owned subsidiary Pharmaceutical Ming Fund, the first phase of investment in the field of rare drugs in Beihai Kangcheng, indirectly improve the field of rare diseases in the field of new drug research and development services, accelerate the integration of the CRO industry chain.
-
How will the anti-corruption in the field of pharmaceutical purchase and sale deepen?
Time of Update: 2021-03-08
The price of metformin hydrochloride tablets used to treat type 2 diabetes was as low as 1.5 cents per tablet, a decrease of more than 90%, and the antibiotic drug lynamine tablets used to treat pneu
-
Yahong Pharma completes the C-round financing to accelerate the pace of commercialization
Time of Update: 2021-03-08
APL-1202, one of The Key Projects of Yahong Pharmaceuticals, is the world's first innovative drug for the oral treatment of non-muscle immersive bladder cancer, which has been registered for clinical development.
-
Provincial new crown vaccine procurement catalogue published
Time of Update: 2021-03-08
The two inactivated vaccines of the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products, which are included in jiangsu's procurement catalogue, and the new crown vaccine of Beijing Koxing Zhongwei Biotechnology Co., Ltd., have entered phase III clinical trials worldwide.
-
Yunding Xinyao completed a $310 million round C financing
Time of Update: 2021-03-08
"Yunding Xinyao has a world-class clinical registration team and an integrated business platform to create a global innovation biopharmaceutical company focused on innovative pharmaceutical research and development and commercialization," said Irene Hong, a partner at Easy Capital, an investment banking consultant on the deal.
-
Active withdrawal of the network or for the pharmaceutical company's 2020 performance "buried thunder"
Time of Update: 2021-03-08
May 25, Shanxi Province drug bidding procurement network hung out two notices, including Chenxin Pharmaceuticals, Chengdu Teo Pharmaceutical Group, Shi Pharmaceutical Group, Ha Pharmaceutical Group, Shenwei Pharmaceuticals and other 25 enterprises applied to withdraw the direct hanging network product platform registration qualification, involving 66 drug regulations, enterprises also made a national unified non-supply commitment.
-
Sena Bio completes hundreds of millions of dollars in C-round financing
Time of Update: 2021-03-08
According to the company's official website, Sena Biotech (Beijing) Co., Ltd. was founded in 2015, is a professional engaged in gene sequencing platform research and development and industrialization, committed to precision medicine high-precision technology development and life science cutting-edge research of high-tech companies.
-
Kyusju Tong acquires step-by-step subsidiary to undertake prescription outflow
Time of Update: 2021-03-07
Data show that Kyusju Tong, as the country's largest private pharmaceutical circulation enterprises, mainly to primary medical institutions pharmacies and private hospitals as the object, to provide drug sales and distribution services, so the company has a strong logistics and distribution capacity and terminal resources.
-
Pharmaceutical companies lost more than 3.5 billion de-market hundreds of billions of "pharmaceutical Maotai" suddenly fell to a halt
Time of Update: 2021-03-07
As of the close of trading on September 18, Hengrui Pharmaceuticals was still in the top spot with a market capitalization of 472.2 billion yuan, followed by Meirui Medical, and the market capitalization of exceeded that of Yunnan White Pharmaceuticals to become the leading market capitalization of the Chinese medicine sector.
-
The company completed round C of $100 million in financing
Time of Update: 2021-03-07
Currently, the company is conducting two Phase I clinical trials initiated by researchers, including the GC012F self-cell candidate developed under the FasTCAR platform for the treatment of recurring or refractic multiple myeloma (r/r MM), and the GC027 isomorphosis product developed under the TruUCAR platform for the treatment of recurring or refractic T-cell acute lymphoblastic leukemia (r/r-ALL).
-
How likely is the patent challenge to win? Look at the attack and defense of pharmaceutical companies
Time of Update: 2021-03-07
However, in January 2018, AstraZeneone filed a formal lawsuit with the Beijing Intellectual Property Court, seeking to revoke the original Patent Review Board's Decision No. 33591 "Patent Invalid" and to order it to review the decision.
-
These are the keys after national volume procurement
Time of Update: 2021-03-07
of 92% is the first step Recently, the first batch of high-value consumables collection officials, a large number of medical device production enterprises participated in this tender collection, both foreign-funded enterprises well-known brands, but also domestic first-line products.
-
East China Pharmaceuticals acquired a 20% stake in Swiss boric acid enterprises plus the layout of the field of medical beauty
Time of Update: 2021-03-07
In the field of anti-tumor, East China Pharmaceuticals and ImmunoGen signed a $305 million cooperation agreement to introduce the world's exclusive anti-ovarian cancer ADC drug, marking the company's full-scale entry into the field of innovative cancer drugs.
